Investigating a protein's role in abdominal aortic aneurysm development
Dedicator of cytokinesis 2 in abdominal aortic aneurysm
This study is looking at how a protein called DOCK2 affects inflammation and the weakening of blood vessels that can lead to abdominal aortic aneurysms (AAA), with the hope of finding new treatments for this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10417112 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, dedicator of cytokinesis 2 (DOCK2), contributes to the inflammation and weakening of blood vessels that lead to abdominal aortic aneurysms (AAA). By studying the mechanisms behind vascular inflammation and extracellular matrix degradation, the research aims to identify potential therapeutic targets. The approach involves using mouse models to observe the effects of DOCK2 deficiency on aneurysm formation and related inflammatory processes. If successful, this research could pave the way for new treatments for AAA, which currently lacks effective pharmacological options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for abdominal aortic aneurysms, particularly those with a family history or other risk factors.
Not a fit: Patients who do not have abdominal aortic aneurysms or related vascular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating abdominal aortic aneurysms.
How similar studies have performed: Other research has shown promising results in understanding the role of inflammatory processes in aneurysm formation, suggesting that this approach could yield valuable insights.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Chen, Shiyou — University of Missouri-Columbia
- Study coordinator: Chen, Shiyou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.